Paul Finnegan is the founder of Angiocrine Bioscience. Angiocrine Bioscience has raised $15M in total funding. Latest round: Series B. Based in San Diego, CA.
Paul Finnegan is the Chief Executive Officer of Angiocrine Bioscience, a clinical-stage biopharmaceutical company. He has led the company through Series B financing, the initiation of a pivotal Phase 3 clinical trial, and has received over $13.5 million in awards from the California Institute for Regenerative Medicine (CIRM).
Full founder directory · Investor directory · Company funding database · Fundraising library